Apogee announced positive 16-week Part B induction dose optimization results from its Phase 2 APEX trial of zumilokibart, with 65.9% of mid-dose patients achieving EASI-75 endpoints. The company plans to advance the mid-dose into Phase 3 trials in 2H 2026 and secured strategic financing from Blackstone Life Sciences to fund development through commercialization.